Hulio (adalimumab-fkjp) is a biosimilar, subcutaneous injection used to treat chronic inflammatory conditions, including rheumatoid arthritis, Crohn's disease, and plaque psoriasis, by blocking tumor necrosis factor. It acts as a tumor necrosis factor (TNF) blocker to reduce pain, swelling, and inflammation.